

LEFT VENTRICULAR NON-COMPACTION: CASE REPORT AND REVIEW OF LITERATURE

ABSTRACT

Non-compaction cardiomyopathy (NCC) is characterized by trabeculations in either one or both ventricles [1]. Clinical presentation is highly variable: dyspnea, palpitation, thromboembolic events, arrhythmia or sudden cardiac death. There is currently no universally-accepted criteria for classifying and diagnosing left ventricular non-compaction cardiomyopathy (LVNC). Transthoracic echocardiography (TTE) has been the diagnostic exam of choice, while the diagnosis is often missed or delayed because of lack of knowledge about this uncommon disease. Progression of LVNC is highly variable and prediction of prognosis is very difficult.

We report a case of a 50-year-old female with a history of total thyroidectomy under hormonal supplementation who consults for dyspnea and paroxysmal palpitations revealing an isolated LVNC. This case emphasizes the importance of imaging techniques, that is, TTE and cardiac magnetic resonance imaging (MRI) in early diagnosis, management, and follow-up.

Keywords: cardiomyopathy, left ventricular non-compaction cardiomyopathy, cardiac magnetic resonance imaging, ventricular trabeculations, spongy myocardium.

1. INTRODUCTION

NCC, also called “spongy myocardium”, is a rare genetic disorder characterized by trabeculations in either one or both ventricles [1]. NCC is found on TTE and/or cardiac MRI. This rare disease is associated with thromboembolism and an increased risk of ventricular thrombus formation and even sudden death. Clinical presentation is highly variable, and can range from asymptomatic disease to symptoms of, bundle branch blocks, sudden cardiac death including palpitations, chest pain, shortness of breath, cerebrovascular accidents revealing heart failure, thromboembolism, and atrial or ventricular arrhythmias. There are currently no universally-accepted criteria for classifying and diagnosing LVNC.

LVNC thought to be caused by arrest of normal embryogenesis of the endocardium and myocardium. It may be associated with other congenital cardiac defects.

We report a case of a 50-year-old female with a history of total thyroidectomy under hormonal supplementation who consults for dyspnea and paroxysmal palpitations revealing an isolated LVNC suspected in TTE and confirmed with cardiac MRI.

2. CASE PRESENTATION

A 50-year-old female with a past medical history of total thyroidectomy under hormonal supplementation who consults for dyspnea for two months prior without any aggravating or alleviating factors. She also complained of more frequent and sustained episodes of rapid palpitations associated with shortness of breath. There was no family history of cardiomyopathy.

Physical examination found a stable patient, with a blood pressure of 138/78mmHg and heart rate of 73 beats per minute. An electrocardiogram (ECG) demonstrated normal sinus rhythm and normal axis, and repolarization disorders with negative T waves in AVL – DI. Biological assessment shows a normal troponin level as well as normal renal and liver function tests.




Fig. 1. Twelve-lead ECG shows sinus rhythm, normal QRS duration, and negative T-wave flattening in aVL, DI

A TTE was performed demonstrating marked thickening trabeculation of the apical half of the left ventricle predominantly at the apex but also in the apical and mid portion of lateral and anterior wall. Colour doppler displayed flow within the deep intertrabecular recesses. The left ventricle was not dilated with a mildly reduced ejection fraction, left ventricular ejection fraction (LVEF) of 45%. The right ventricle was normal. No additional abnormalities were seen. We concluded to an isolated non-compaction of the ventricular myocardium (Figures 2-3). A cardiac catheterization did not reveal evidence of obstructive coronary artery disease. Twenty-four-hour Holter monitoring identified frequent premature ventricular contractions (PVC).




Fig. 2. 2D echocardiography: apical four-chamber (A4c) and short axis showing trabeculation of the apex, the medium and apical segment of the interventricular septum, and the lateral wall.




Fig. 3. 2D speckle tracking echocardiography

Given the strong suspicion of non-compaction, a cardiac MRI was indicated and it demonstrated trabeculated aspect of the pillars, hypertrabeculation of the left ventricle with a ratio of non-compacted to compacted myocardium of 2.7. We noted the presence of an anterior new cavity measuring 44x25mm created by the trabeculation. The tagging sequence showed an alteration of the intrinsic contractility of the anterior wall. There was no late gadolinium enhancement suggestive of myocardial infarction or fibrosis. (Figures 4-5).




Fig. 4. Four-chamber view of cardiac MRI revealing a LVNC (diastolic and systolic).




Fig. 5. Short axis view of cardiac MRI revealing a LVNC (diastolic and systolic).

Our patient was started on treatment of heart failure and acenocoumarol 4 mg daily as an indefinitely therapy with an international normalized ratio (INR) goal of 2-3. The patient will have regular follow-ups for arrhythmia screening and monitoring of her left ventricular function. The available literature indicates that warfarin will be effective at preventing further embolic events.

Familial screening of first-degree relatives was also negative for LVNC, and congenital heart disease. The patient was, then, put on aspirin, beta blocker, angiotensin-receptor blocker, and anticoagulation therapy with acenocoumarol.

Today, after two years of follow-up under treatment, we noted a good evolution of the symptoms, regression of the episodes of palpitations without any clinical or echocardiographic thrombo-embolic incident.

3. DISCUSSION

NCC is a rare genetic cardiomyopathy [1] first described in 1932 when Bellet et al reported this anomaly in newborns with aortic atresia and coronary artery-left ventricular fistula. It is characterized by excess of trabeculations in the endocardium, affecting one or both ventricles [2].

LVNC is a rare cardiomyopathy. Prevalence is less than 0.02% and is male predominant [1]. It is often familial with an autosomal dominant mode with defects in genes coding for sarcomere, cytoskeleton, and mitochondrial proteins or sporadic [3].

ECG can be normal, or showing early repolarization abnormalities, QTc prolongation repolarization, atrial fibrillation, paroxysmal supraventricular tachycardia and complete heart block [4].

The most used method of diagnosis is TTE [5] confirmed by the cardiac MRI with a ratio between the end-systolic thickness of the compacted vs noncompacted tissue of greater than 2.0. Recent reports indicate high sensitivity and specificity using a ratio of >2.3 [5].

There are two sets of echocardiographic criteria: the Jenni criteria focused on the presence of a two-layered structure [6], and the Chin criteria focused on the depth of the recess compared with the height of the trabeculations [7]. Jenni criteria are the most accepted validated echocardiographic criteria and consist of evidence of a two-layer structure: a compacted layer and a noncompacted endocardial layer. In the short-axis view, the end-systolic ratio of noncompacted to compacted layers (NC/C) >2.0 is compatible with the diagnostic [6]. Additional criteria that must be met include the absence of any coexisting cardiac abnormalities and colour doppler evidence of deep perfused intertrabecular recesses [6]. Chin criteria [7] considered for diagnosis are the presence of numerous excessively prominent trabeculations and deep intertrabecular recesses with the ratio of the distance from the epicardial surface to the trough of the trabecular recesses and distance from the epicardial surface to the peak of trabeculation ≤ 0.5 , assessed at end-diastole on short-axis parasternal views and/or apical views. It is also important that no other cardiac structural abnormalities be present [7]. Stollberger *et al.* defined LVNC as trabeculations $>/3$, prominent formations along the left ventricular endocardial border, located apically to the papillary muscles, visible in end-diastole, in one imaging plane, moving synchronously with the compacted myocardium, distinct from the papillary muscles, false tendons, or aberrant bands [8].

Ghebhard *et al.* considered compacted myocardium systolic thickness <8 mm for diagnosis of LVNC [9].

In difficult cases, other echocardiographic techniques can be used for diagnosis: contrast enhancement, three-dimensional echocardiography, speckle tracking, and tissue doppler imaging. Speckle-tracking echocardiography was used in borderline cases because LVNC affects the left ventricle twist [10].

LVNC is usually associated with cardiac structural abnormalities, reduced ejection fraction or systolic dysfunction, attributed to pathogenic ischemic and damaged endocardium, as evidenced by fibrotic changes on

cardiac MRI and to asynchronism of contraction between the compacted and noncompacted myocardial layers [4]. Isolated NCC can occur as well.

Cardiac MRI plays a pivot role in diagnosis of LVNC. *Petersen et al* suggest that LVNC is diagnosed accurately with cardiac MRI using the NC/C ratio in diastole. A NC/C ratio of >2.3 in diastole distinguished pathological non-compaction, with values for sensitivity, specificity, and positive and negative predictions of 86%, 99%, 75%, and 99%, respectively [11]. For the *Grothoff* criterion, the NC/C ratio is measured in diastolic short-axis views, and the cutoff for LVNC is $NC/C \geq 3$ [12]. The *Stacey* criterion is calculated from end-systolic short-axis views, with $NC/C \geq 2$ considered positive for an LVNC [13]. The *Jacquier* criterion is estimated from the noncompacted myocardial mass as a percentage of total LV mass; a noncompacted mass $\geq 20\%$ is considered to indicate an LVNC phenotype [14].

We expose some studies based on TTE and MRI to define a LVNC (Figure 6) [15].

TABLE 1 Examples of Echocardiographic and CMR Approaches to Determining the Extent of LV Trabeculations					
Modality	Jenni et al ³	Petersen et al ¹⁷	Jacquier et al ¹⁰⁵	Stacey et al ¹³⁹	Captur et al ¹⁴⁰
	Echocardiography	CMR	CMR	CMR	CMR
Sample size	Noncompaction (n = 34) No control group	Noncompaction (n = 7) Control subjects (n = 170)	Noncompaction (n = 16) Control subjects (n = 48)	Noncompaction (n = 122) No control group	Noncompaction (n = 30) Control subjects (n = 105)
Study design/external validation	Retrospective/no external validation cohort	Retrospective/no external validation cohort	Retrospective/no external validation cohort	Retrospective/no external validation cohort	Retrospective/no external validation cohort
Definition of noncompaction	Absence of coexisting cardiac disease Numerous excessively prominent trabeculations and deep intertrabecular recesses Intertrabecular spaces filled by direct blood flow from the ventricular cavity, on color Doppler imaging	Bilayered appearance on echocardiography combined with increased pretest probability (eg, similar appearance in first-degree relatives, associated neuromuscular disorder, or complications, such as systemic embolization and regional wall motion abnormalities)	Diagnosis of noncompaction was established on echocardiographic criteria	Consecutive patients from CMR reports that mention trabeculation or noncompaction	Diagnosis of noncompaction on echocardiographic criteria and at least 1 of the following: positive family history, associated neuromuscular disorder, regional wall motion abnormality, noncompaction-related complications (arrhythmia, heart failure, or thromboembolism)
Description	Noncompaction to compaction ratio Decreased thickening and hypokinesia present within, but not limited to, the noncompacted segments	Two-layered myocardium Measured at the most pronounced trabeculations, avoiding apex Measurement perpendicular to compact myocardium	Short-axis cines for total LV mass and compact mass to define trabecular mass Papillary muscle included in the myocardial mass	Apical short-axis views 16–24 mm from the true apical slice Region with the largest noncompaction to compaction ratio	Loss of base-to-apex fractional dimension gradient
Cardiac phase	End-systole	End-diastole	End-diastole	End-systole	End-diastole
Cardiac view	Short axis	Long axes (4-chamber, 2-chamber, 3-chamber)	Short-axis stack	Apical short axis	Short-axis stack
Excessive trabeculation cutoff	Noncompaction to compaction ratio >2	Noncompaction to compaction ratio >2.3	Trabecular mass $>20\%$	Noncompaction to compaction ratio ≥ 2	Fractal dimension ≈ 1.30

Fig. 6. Definitions highlight variation in current definitions of excessive trabeculation.

There is no therapy specific for patients with LVNC. Treatment is focused on complications, that is, heart failure, systemic embolism, and sudden cardiac death [16]. Management of symptomatic patient's heart failure is with digoxin, diuretics, angiotensin-converting enzyme inhibitors, beta-blockers. Some patients undergo cardiac transplantation. Cardiac rhythm abnormalities are managed with standard protocol, while some patients may benefit from an implanted cardiac defibrillator for severe ventricular tachyarrhythmias to prevent sudden death [17].

Hypertrabeculation predisposed patients with reduced left the ventricular function are at risk for clot formation. Some literature supports the use of anticoagulation in patients with $LVEF \leq 40\%$, a history of atrial fibrillation, or a prior cardioembolic event. Whether anticoagulants should be administered to every LVNC patient is, however, still debated. Anticoagulation therapy must be targeted to the individual patient after careful assessment of the benefit and risks. Oral anticoagulation therapy (target INR 2.0–3.0) was recommended in patients with impaired systolic function, previous history of embolism, transient ischemic attack, atrial fibrillation, and intracardiac thrombi identified on echocardiogram or another cardiac imaging modality [20].

Otherwise, risk assessment based on CHADS₂/CHADS₂-VASc scores similar to that used to stratify stroke risk in patients with atrial fibrillation as guidance and preference of the patient is recommended [18],[19]. However, the length of anticoagulation therapy in these patients has not been established. If using warfarin, a targeted INR range of 2-3 has been proposed [9].

Patients with LVNC and sustained ventricular tachycardia or ventricular fibrillation require cardioverter-defibrillator implantation (ICD). These patients are at higher risk for SCD, even with normal ejection fraction. This should be based on current ICD primary and secondary prevention guidelines. ICD for primary prevention

of sudden cardiac death is indicated for patients with LVNC who present with LVNC and LVEF \leq 35%. Patients with malignant ventricular tachyarrhythmia should undergo ICD implantation for secondary prevention [20]. The outcomes of transplantation have yet to be established. Follow-up consists of symptom assessment, LVEF monitoring, and arrhythmia screenings, including electrophysiology evaluation if needed [9],[20]. All patients should also receive family and genetic counselling [9].

4. CONCLUSION

LVNC is an uncommon cause of cardiomyopathy. A gold standard for diagnostic criteria has not been established. Further research and collaboration from major organizations are necessary to create a standardized criteria for the diagnosis and management of this pathology. The management and treatment of each case of LVNC should be individualised to each patient. All patients should also receive family and genetic counselling.

2D-echocardiography and cardiac MRI play a pivotal role in the diagnosis and management of LVNC. However, more studies are needed to establish the choice and duration of anticoagulants, including the efficacy and safety of direct oral anticoagulant in LVNC.

REFERENCES

- [1] Wengrofsky P, Armenia C, Oleszak F, *et al.* Left ventricular trabeculation and noncompaction cardiomyopathy: a review. *EC Clin Exp Anat.* 2019;2(6):267–83.
- [2] P. Elliott, B. Andersson, E. Arbustini *et al.* Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. *European Heart Journal*, 29 (2008), pp. 270-276
- [3] Oechslin E, Jenni R. Left ventricular noncompaction from physiologic remodeling to noncompaction cardiomyopathy. *J Am Coll Cardiol.* 2018
- [4] Weiford BC, Subbarao VD, Mulhern KM. Noncompaction of the ventricular myocardium. *Circulation.* 2004;109:2965–71
- [5] Thomas DE, Wheeler R, Yousef ZR, Masani ND. The role of echocardiography in guiding management in dilated cardiomyopathy. *Eur J Echocardiogr.* 2009
- [6] Jenni R, Oechslin E, Schneider J, *et al.* Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy. *Heart.* 2001;86:666–71
- [7] Chin TK, Perloff JK, Williams RG, *et al.* Isolated noncompaction of left ventricular myocardium. A study of eight cases. *Circulation.* 1990;82(2):507–13
- [8] Stollberger C, Finsterer J. Left ventricular hypertrabeculation/noncompaction. *J Am Soc Echocardiogr.* 2004;17:91–100
- [9] Gebhard C, Stahli BE, Greutmann M, *et al.* Reduced left ventricular compacta thickness: a novel echocardiographic criterion for non-compaction cardiomyopathy. *J Am Soc Echocardiogr.* 2012;25(10):1050–7.
- [10] Niemann M, Liu D, Hu K, *et al.* Echocardiographic quantification of regional deformation helps to distinguish isolated left ventricular non-compaction from dilated cardiomyopathy. *Eur J Heart Fail.* 2012;14:155–6
- [11] Petersen SE, Selvanayagam JB, Wiesmann F, Robson MD, Francis JM, Anderson RH, Watkins H, Neubauer S. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. *J Am Coll Cardiol.* 2005 Jul 5;46(1):101-5.
- [12] M. Grothoff, M. Pachowsky, J. Hoffmann, *et al.* Value of cardiovascular MR in diagnosing left ventricular non-compaction cardiomyopathy and in discriminating between other cardiomyopathies *Eur Radiol*, 22 (2012), pp. 2699-2709.
- [13] R.B. Stacey, M.M. Andersen, M. St Clair, W.G. Hundley, V. Thohan Comparison of systolic and diastolic criteria for isolated LV noncompaction in CMR *J Am Coll Cardiol Img.* 6 (2013), pp. 931-940
- [14] A. Jacquier, F. Thuny, B. Jop, *et al.* Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. *Eur Heart J*, 31 (2010), pp. 1098-110
- [15] Petersen S, Jensen B, Aung N, *et al.* Excessive Trabeculation of the Left Ventricle. *J Am Coll Cardiol Img.* 2023 Mar, 16 (3) 408–425.
- [16] Bennett CE, Freudenberger R. The current approach to diagnosis and management of left ventricular noncompaction cardiomyopathy: review of the literature. *Cardiol Res Pract.* 2016;2016:7
- [17] Klenda J, Boppana LKT, Vindhya MR. Heart Failure Secondary to Left Ventricular Non-compaction Cardiomyopathy in a 26-Year-Old Male. *Cureus.* 2018 Jul 20;10(7):e3011

- [18] Bennett CE, Freudenberg R. The current approach to diagnosis and management of left ventricular noncompaction cardiomyopathy: review of the literature. *Cardiol Res Pract.* 2016;2016:7
- [19] K. Kido and M. Guglin, "Anticoagulation Therapy in Specific Cardiomyopathies: Isolated Left Ventricular Noncompaction and Peripartum Cardiomyopathy," *Journal of Cardiovascular Pharmacology and Therapeutics*, vol. 24, no. 1, pp. 31–36, 2019
- [20] Silvia G, Priori SG, Blomstro C, Andrea Mazzanti A, et al. ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *Eur Heart J.* 2015;36:2793–867

UNDER PEER REVIEW